Characteristics Associated with Accelerated Lung Function Decline in a Primary Care Population with Chronic Obstructive Pulmonary Disease

Abstract

Background

Estimates for lung function decline in chronic obstructive pulmonary disease (COPD) have differed by study setting and have not been described in a UK primary care population.

Purpose

To describe rates of FEV ₁ and FVC decline in COPD and investigate characteristics associated with accelerated decline.

Patients and Methods

Current/ex-smoking COPD patients (35 years+) who had at least 2 FEV ₁ or FVC measurements ≥6 months apart were included using Clinical Practice Research Datalink. Patients were followed up for a maximum of 13 years. Accelerated rate of lung function decline was defined as the fastest quartile of decline using mixed linear regression, and association with baseline characteristics was investigated using logistic regression.

Results

A total of 72,683 and 50,649 COPD patients had at least 2 FEV ₁ or FVC measurements, respectively. Median rates of FEV ₁ and FVC changes or decline were −18.1mL/year (IQR: −31.6 to −6.0) and −22.7mL/year (IQR: −39.9 to −6.7), respectively. Older age, high socioeconomic status, being underweight, high mMRC dyspnoea and frequent AECOPD or severe AECOPD were associated with an accelerated rate of FEV ₁ and FVC decline. Current smoking, mild airflow obstruction and inhaled corticosteroid treatment were additionally associated with accelerated FEV ₁ decline whilst women, sputum production and severe airflow obstruction were associated with accelerated FVC decline.

Conclusion

Rate of FEV ₁ and FVC decline was similar and showed similar heterogeneity. Whilst FEV ₁ and FVC shared associations with baseline characteristics, a few differences highlighted the importance of both lung function measures in COPD progression. We identified important characteristics that should be monitored for disease progression.

Journal

Journal ID (nlm-ta): Int J Chron Obstruct Pulmon Dis

Journal ID (iso-abbrev): Int J Chron Obstruct Pulmon Dis

Journal ID (publisher-id): copd

Journal ID (pmc): copd

Title: International Journal of Chronic Obstructive Pulmonary Disease

Publisher: Dove

ISSN (Print): 1176-9106

ISSN (Electronic): 1178-2005

Publication date (Electronic): 25 November 2020

Publication date Collection: 2020

Volume: 15

Pages: 3079-3091

Affiliations

[1 ]Respiratory Epidemiology, Occupational Medicine and Public Health, National Heart and Lung Institute, Imperial College London , London, UK

[2 ]Epidemiology (Value Evidence and Outcomes), GlaxoSmithKline, R&D , Uxbridge, UK

[3 ]MRC Biostatistics Unit, University of Cambridge , Cambridge, UK

Author notes

Correspondence: Hannah R Whittaker Imperial College, Emmanuel Kaye Building, National Heart and Lung Institute , London, UK Email [e-mail]

Article

Publisher ID: 278981

DOI: 10.2147/COPD.S278981

PMC ID: 7701160

PubMed ID: 33268984

Copyright statement: © 2020 Whittaker et al.

License:

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

Page count

Figures: 3, Tables: 6, References: 63, Pages: 13

Funding

Funded by: GSK, open-funder-registry 10.13039/100004330;

This manuscript was funded by GSK; study number 209427.

Categories

Subject: Original Research